BP. 13, 14 Recently, it has been reported that high level of aldosterone inhibited the early EPC formation from bone marrow precursor cells 15 and vascularization capacity, 16 suggesting that hyperaldosteronemia might also influence the early EPCmediated endogenous repair mechanism apart from the direct detrimental effect on vascular wall. However, the in vivo effect of hyperaldosteronemia on early EPC function, especially the endothelial repair capacity, needed to be further determined. Therefore, in the present study, we compared the early EPC in vivo endothelial repair capacity of PHAs to ageand BP-matched EHs and age-matched healthy subjects (HSs) and analyzed the underlying molecular mechanism.
It has been demonstrated that aldosterone is a strong mediator stimulating oxidative stress in vascular cells. 17 Oxidative stress-led 5,6,7,8-tetrahydrobiopterin (BH 4 ) degradation is the main pathogenic cause of endothelial nitric oxide synthase (eNOS) uncoupling. 18, 19 The eNOS uncoupling has been proved as an important molecular mechanism underlying atherosclerotic vascular disease. 19, 20 On the basis of these data, we hypothesized that oxidative BH 4 degradation and eNOS uncoupling may involve in the hyperaldosteronemia-caused alteration of early EPC function. Therefore, in the present study, we attempted to clarify the role of oxidative stress and BH 4 bioavailability and eNOS/NO pathway in the regulation of early EPC-mediated endothelial repair in PHAs.
Methods

Study Subjects
Twenty patients identified with an aldosterone-producing adenoma, thus PHAs based on increased aldosterone/renin ratio (>50) and pathological saline infusion test and imaging test via high-resolution computed tomographic scan were recruited. All the patients were retrospectively defined to aldosterone-producing adenoma by histopathology after surgical treatment. All the antihypertensive drugs were stopped >2 weeks for the diagnostic tests before recruitment. After recruitment, all the PHAs were treated with spironolactone (60-120 mg/d) for 4 to 6 weeks before surgical treatment. Twenty newly diagnosed EHs without pharmacological therapy randomly matched for age and BP to enlisted PHAs were recruited from patients visited in the First Affiliated Hospital of Sun Yat-Sen University (Guangzhou, China). Twenty age-matched HSs were recruited as the controls. The PHAs and EHs were included without other known cardiovascular disease, and the included HSs had no cardiovascular risk factors. All the study subjects were excluded diabetes mellitus, malignant disease, infection, or inflammatory disorders. BP measurements were performed according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. All of the subjects underwent 3 BP measurements in 2 different visits, after 30 minutes of rest, and the measurements were spaced by 5-to 10-minute intervals, on both the left and right arm, in the sitting and lying positions. The clinical characteristics are summarized in Table S1 in the online-only Data Supplement. Our study was confirmed to the ethical principles outlined in the Declaration of Helsinki. The experimental protocol was approved by the Ethical Committee of the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China), and written informed consent was obtained from every study participant.
Statistical Analysis
All results are expressed as mean±SEM. Comparisons between groups were analyzed by the Student t test. Statistical analysis was performed by a 1-way ANOVA, followed by multiple comparisons using either the Student-Newman-Keuls or Tukey-Kramer test. A value of P<0.05 was considered to denote statistical significance.
All statistical analyses used SPSS statistical software (SPSS version 13.0).
Other detailed methods performed in the present study are provided in the online-only Data Supplement.
Results
In Vivo Endothelial Repair Capacity of Early EPCs From PHAs, EHs, and HSs
In vivo endothelial repair area was evaluated by Evans Blue staining, and the representative photographs are shown in Figure 1B . Transplantation of early EPCs accelerated in vivo endothelial repair of denudated injured carotid artery markedly compared with PBS injection ( Figure 1A ). In vivo endothelial repair capacity of early EPCs from PHAs and EHs was obviously impaired when compared with HSs ( Figure 1A ). The in vivo endothelial repair capacity of early EPCs from PHAs was impaired more severely than from EHs ( Figure 1A ). After oral spironolactone for 4 to 6 weeks, in vivo endothelial repair capacity of early EPCs from PHAs was significantly improved ( Figure 1A ). Phycoerythrin-conjugated monoclonal mouse anti-human CD14 antibody-labeled early EPCs were detected homing to the sites of the injured carotid arteries but not in the contralateral uninjured carotid arteries via both the confocal laser scanning microscopy analysis ( Figure S2A ) and the fluorescence-activated cell sorter analysis ( Figure  S2B ). The cultured human umbilical vein endothelial cells were injected into the tail vein of nude mice with carotid injury as the negative control. After human umbilical vein endothelial cells injection, little phycoerythrin-conjugated monoclonal mouse anti-human CD14 antibody-labeled cells were detected homing to the sites of the injured carotid arteries via the confocal laser scanning microscopy analysis and fluorescence-activated cell sorter analysis (data not shown). Moreover, human umbilical vein endothelial cells injection did not improve endothelial repair ( Figure S2C ).
In vitro early EPC function, such as migration to vascular endothelial growth factor/stromal cell-derived factor-1 and adhesion to fibronectin in flow, was also evaluated in the present study. As the results shown in Figure S4 , in vitro migration and adhesion activity of early EPCs were impaired obviously in PHAs and EHs when compared with HSs, and a further impairment was shown in PHAs compared with EHs. The in vitro migration and adhesion activity of early EPCs in PHAs were obviously promoted after oral spironolactone treatment ( Figure S4 ). The number of circulating EPCs (as assessed by CD34/kinase-insert domain receptor double-positive or CD133/kinase-insert domain receptor double-positive peripheral blood mononuclear cells via fluorescence-activated cell sorter) has no significant difference from PHAs, EHs, and HSs ( Figure S5 ); similar to previous study, 16 data reported here suggested that hyperaldosteronemia leads to qualitative rather than quantitative impairment on circulating EPCs.
Endothelial Function in PHAs, EHs, and HSs
Endothelial function expressed as the flow-mediated dilation (FMD) of brachial artery was obviously reduced in PHAs and EHs when compared with HSs ( Figure 1C) , and FMD by guest on January 28, 2018 http://hyper.ahajournals.org/ Downloaded from was reduced more in PHAs than in EHs ( Figure 1C ). After oral spironolactone for 4 to 6 weeks, the FMD in PHAs was markedly improved ( Figure 1C ). In vivo endothelial repair capacity of early EPCs was positively related to FMD ( Figure 1D ).
Increased Oxidative Stress in Early EPCs From PHAs
Oxidative stress level of early EPCs was evaluated by intracellular reactive oxygen species (ROS) production via 2′,7′-dichlorodihydrofluorescein diacetate fluorescence and superoxide production via electron paramagnetic resonance spectroscopy analysis, respectively. Intracellular ROS production ( Figure 2A ) and superoxide production ( Figure 2B and 2C) were obviously increased in early EPCs from PHAs when compared with HSs. After oral spironolactone for 4 to 6 weeks, both the intracellular ROS production ( Figure 2A ) and the superoxide production ( Figure 2B and 2C) were reduced in early EPCs from PHAs.
Increased p47 phox Transcription and Translocation to Plasma Membrane in Early EPCs From PHAs
The important nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit p47 phox transcription of early EPCs from PHAs was obviously increased compared with HSs ( Figure 2D ). The membrane localization of p47 phox protein was also increased in early EPCs from PHAs when compared with HSs ( Figure 2E ). After oral spironolactone for 4 to 6 weeks, p47 phox transcription and translocation of early EPCs from PHAs were obviously inhibited ( Figure 2D and 2E). The transcription and expression of NADPH oxidase isoforms (NOX1, NOX2, and NOX4) in early EPCs showed no apparent difference between the HSs and the PHAs ( Figure S6) ; the result was consistent with the in vitro effect of aldosterone on endothelial cells reported by Nagata et al 21 previously.
Decreased NO Generation in Early EPCs From PHAs
NO generation was evaluated both as intracellular cGMP concentration via ELISA system and l-arginine/l-citrulline conversion via high-performance liquid chromatography system analysis. Our data showed that NO generation was obviously decreased in early EPCs from PHAs when compared with HSs ( Figure 3A and 3B). After oral spironolactone for 4 to 6 weeks, NO generation was restored in early EPCs from PHAs ( Figure 3A and 3B). The representative chromatograms of high-performance liquid chromatography for l-arginine/lcitrulline conversion are shown in Figure 3C .
Oxidative BH 4 Degradation and eNOS Uncoupling in Early EPCs From PHAs
BH 4 plays a crucial role as a cofactor of eNOS for generating NO. In its absence, eNOS produces superoxide rather than Figure 1 . In vivo endothelial repair capacity of early endothelial progenitor cells (EPCs) and relation to endothelial function. A, Endothelial repair at day 3 after carotid injury in nude mice with PBS injection (n=20) or transplantation of early EPCs from healthy subjects (HSs; n=20), essential hypertension patients (EHs; n=20), and primary hyperaldosteronemia patients (PHAs; n=20) before or after treatment with spironolactone (Spi). B, Representative photographs: denudated-endothelium area was stained in blue; endothelial repair area in white. C, Endothelial function was evaluated by flow-mediated dilation (FMD) expressed as the percentage change of the brachial artery diameter. D, Relationship between early EPC in vivo endothelial repair capacity and FMD of the subjects (■, HSs, n=20; ◆, EHs, n=20; ▲, PHAs, n=20; •, PHAs after treatment with Spi, n=20).
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http://hyper.ahajournals.org/ Downloaded from NO, 19 which was reported to mechanistically correlate with EPC dysfunction. 22 Therefore, we detected the intracellular biopterin content via high-performance liquid chromatography system and analyzed the amount of BH 4 in early EPCs. There was no obvious difference of the total biopterin content in early EPCs from PHAs and HSs ( Figure 4A and 4B ). In the early EPCs from PHAs compared with HSs, the BH 4 content was substantially reduced, and the oxidized forms of BH 4 (BH 2 and biopterin) were correspondingly increased ( Figure 4A and 4B). After oral spironolactone for 4 to 6 weeks, oxidation of BH 4 in early EPCs from PHAs was obviously attenuated and BH 4 content was significantly increased ( Figure 4A and 4B) .
The eNOS uncoupling-dependent impairment of NO production was mechanistically involved in EPC dysfunction, 22 and the decreased eNOS dimer/monomer ratio can be served as a marker of eNOS uncoupling. 21, 22 Therefore, we performed low-temperature SDS-PAGE and immunoblotting to investigate eNOS dimerization. There was no difference in total eNOS expression in early EPCs from PHAs and HSs using conventional SDS-PAGE ( Figure 4C ), but low-temperature SDS-PAGE showed that the eNOS dimer/monomer ratio was decreased in early EPCs from PHAs compared with HSs ( Figure 4C ). After oral spironolactone for 4 to 6 weeks, the eNOS dimer/monomer ratio in early EPCs from PHAs was markedly increased ( Figure 4C ). Reactive oxygen species (ROS) and superoxide production, p47 phox transcription and membrane localization. A, Semiquantitative analysis of intracellular ROS production via 2′,7′-dichlorodihydrofluorescein diacetate (DCF) fluorescence intensity in early endothelial progenitor cells (EPCs) from healthy subjects (HSs; n=12) and primary hyperaldosteronemia patients (PHAs; n=10) before or after treatment with spironolactone (Spi). B, Electron paramagnetic resonance (EPR) spectroscopy analyses of superoxide production of early EPCs from HSs (n=8) and PHAs (n=10) before or after treatment with Spi. C, The representative EPR spectra of superoxide production. D, The p47 phox transcription of early EPCs from HSs (n=12) and PHAs (n=10) before or after treatment with Spi was detected by real-time reverse transcriptase-polymerase chain reaction. The GAPDH was used as the internal control. E, The membrane and cytosol fractions of p47 phox protein were analyzed by immunoblotting in early EPCs from HSs (n=12) and PHAs (n=10) before or after treatment with Spi. Total cell lysate immunoblotted with actin for control. Figure 5A and 5B) and BH 4 oxidation ( Figure 5E ) and eNOS uncoupling ( Figure 5F ), as well as increased NO generation ( Figure 5C and 5D) of early EPCs from PHAs. Importantly, p47
phox -siRNA significantly improved in vivo endothelial repair capacity of early EPCs from PHAs ( Figure 5G and 5H). Correspondingly, the in vitro migration and adhesion activity of early EPCs from PHAs were promoted by p47 phox -siRNA ( Figure S8 ).
BH 4 Promoted In Vivo Endothelial Repair Capacity of Early EPCs From PHAs
Although BH 4 treatment (1 mmol/L) did not change ROS production (data not shown) and oxidative BH 4 degradation ( Figure 6A ) of early EPCs from PHAs, it increased the total biopterin and BH 4 content ( Figure 6A ) of early EPCs from PHAs. Correspondingly, BH 4 treatment was able to attenuated eNOS uncoupling ( Figure 6B ) and increased NO generation ( Figure 6C and 6D), as well as promoted in vivo endothelial repair capacity ( Figure 6E and 6F) of early EPCs from PHAs. Moreover, the in vitro migration and adhesion activity of early EPCs from PHAs were also enhanced by BH 4 treatment ( Figure S8 ).
Discussion
The present study demonstrated first that in vivo endothelial repair capacity of early EPCs was severely impaired in PHAs accompanied with endothelial dysfunction. Increased oxidative stress, oxidative BH 4 degradation, eNOS uncoupling, and reduced NO generation were observed to mechanistically correlate with impaired in vivo endothelial repair capacity of early EPCs from PHAs. Oral mineralocorticoid receptor (MR) antagonist spironolactone improved the early EPC in vivo endothelial repair capacity and endothelial function of PHAs. Knockdown of the NADPH oxidase subunit p47 phox via siNRA or BH 4 treatment was able to restore early EPC in vivo endothelial repair capacity of PHAs.
Abnormalities in endothelial structure and function thought as important processes underlying the development of atherosclerotic vascular disease are likely the result of imbalance between endothelial damage and repair. 23, 24 The early EPCs, also termed as monocytic EPCs or circulating angiogenic cells, 25 have been proved homing to injured vascular wall and promoting endothelial repair by direct and indirect mechanism in our [8] [9] [10] and other previous studies. 6, 7 To investigate the homing and endothelial repair capacity of early EPCs derived from clinical subjects in vivo, the athymic nude mice with carotid endothelial denuded injury were introduced to accept human early EPC transplantation in the present study. This nude mouse model was usually used in experiments for EPC transplantation research; the data of our and other previous studies [6] [7] [8] [9] [10] indicated that this nude mouse model can nearly avoid species rejection and satisfy the EPC transplantation research. In the present study, the confocal laser scanning microscopy analysis showed a subendothelial homing of intravenously injected early EPCs on the endothelial repair zone of the injured carotid artery, what the result in line with the recent study by Giannotti et al 7 suggested that early EPCs promote the endothelial repair process likely, in particular, by paracrine mechanisms. However, the beneficial effect of early EPCs for endothelial repair was limited when the functional impairment occurred in the presence of some cardiovascular risk factors.
11 Raising BP regardless of whether the cause is essential or secondary to endocrine or renal processes is positively correlated with the incidence of cardiovascular events and leads to endothelial injury. Impaired endothelial repair capacity of early EPCs accompanied by endothelial dysfunction in EHs has been reported previously. 7 The present study provided the first evidence that in vivo endothelial repair capacity of early EPCs was also impaired in secondary hypertensive patients with PHA, suggesting a novel pathological mechanism for ) . B, Intracellular biopterin content was detected by HPLC system in early EPCs from healthy subjects (HSs; n=12) and primary hyperaldosteronemia patients (PHAs; n=10) before or after treatment with spironolactone (Spi). *P<0.01 vs BH 4 content of early EPCs from HSs, **P<0.01 vs oxidized biopterin content of early EPCs from HSs, #P<0.01 vs BH 4 content of early EPCs from PHAs before Spi treatment, ##P<0.01 vs oxidized biopterin content of early EPCs from PHAs before Spi treatment. C, The eNOS dimerization of early EPCs from HSs (n=12) and PHAs (n=10) before or after treatment with Spi was analyzed by low-temperature SDS-PAGE and immunoblotting; quantification expressed as eNOS dimer/monomer rate. by guest on January 28, 2018 http://hyper.ahajournals.org/ Downloaded from vascular complications caused by hyperaldosteronemia. To further investigate the possible difference between the EHs and the PHAs on the early EPC-based endogenous endothelial repair capacity, we compared the in vivo endothelial repair capacity of early EPCs from PHAs to the age-and BP-matched EHs in the present study. We found that in vivo endothelial repair capacity of early EPCs from EHs was impaired when compared with HSs similar with previous study, 7 but the early EPCs from PHAs showed a more severely impaired in vivo endothelial repair capacity than from EHs. Correspondingly, a further reduced FMD was showed in PHAs when compared with age-and BP-matched EHs. These results provided further evidence to prove that impaired early EPC-mediated endogenous endothelial repair capacity contributes to endothelial dysfunction and proposed a novel mechanism to explain the increased rate of cardiovascular events in PHAs when compared with EHs independent of BP.
Increasing evidence indicates that acute and chronic oxidative stress in cardiovascular system is an essential molecular mechanism underlying the development of atherosclerotic vascular disease. 26 Previous studies reported that aldosterone treatment in vitro induced ROS production of early EPCs. 15, 16 In the present study, we observed that the intracellular ROS and superoxide production were obviously increased in early EPCs from PHAs, which further proved that the high level of aldosterone induced oxidative stress of early EPCs in vivo. In endothelial cells, aldosterone-induced oxidative stress increases oxidative degradation of BH 4 that leads to eNOS uncoupling and subsequently decreased NO generation. 21 The eNOS uncoupling has also been reported to contribute to EPC functional impairment. 22 The oxidative BH 4 degradation and eNOS uncoupling and decreased NO generation were showed in early EPCs from PHAs in the present study as well, suggesting that oxidative BH 4 degradation and derangement of eNOS/NO pathway may be also involved in the functional impairment of early EPCs in PHAs.
One main source of superoxide in vasculature stimulated by aldosterone is the NADPH oxidase. 27 Nagata et al 21 have recently proved that p47 phox subunit of the NADPH oxidase plays an important role in aldosterone-stimulated ROS production in endothelial cells. 21 The present study showed an obviously increased p47 phox transcription and translocation to the plasma membrane fraction in early EPCs from PHAs, indicating the NADPH oxidase activation. To further investigate the connection between the increased ROS production and the NADPH oxidase activation, we treated early EPCs of PHAs with p47 phox -siRNA or NADPH oxidase inhibitor apocynin. It showed clearly that either p47 phox -siRNA or apocynin markedly inhibited the oxidative stress of early EPCs from PHAs. In parallel, BH 4 oxidation and eNOS uncoupling were attenuated, and NO generation was increased in early EPCs from PHAs by p47 phox -siRNA. Importantly, p47 phox -siRNA restored in vivo endothelial repair capacity of early EPCs from PHAs. The eNOS was also recognized to be a source of superoxide with the BH 4 deficiency. To identify the source of superoxide production in early EPCs from PHAs, the early EPCs of PHAs were treated with eNOS inhibitor l-nitro-arginine methyl ester. The data showed that l-nitro-arginine methyl ester treatment had little effect to inhibit superoxide production of early EPCs from PHAs when compared with apocynin ( Figure S9 ). These data indicated that hyperaldosteronemia impaired in vivo endothelial repair capacity of early EPCs via increased oxidative stress derived from activating NADPH oxidase rather than uncoupling eNOS. The oxidative BH 4 degradation and derangement of eNOS/NO pathway were the subsequent alteration of increased oxidative stress and took part in hyperaldosteronemia-caused functional impairment of early EPCs. BH 4 has been recognized gradually as a potential therapeutic target in atherosclerotic vascular disease for regulating eNOS activity. 19 Supplementation with BH 4 was able to slow the progression of atherosclerosis. 28 Recently, Nagata et al 21 reported that BH 4 treatment prevented aldosterone-induced eNOS uncoupling of endothelial cells. In the present study, the high-performance liquid chromatography analysis showed that BH 4 treatment increased intracellular BH 4 content of early EPCs from PHAs, indicating that intracellular BH 4 can be supplemented exogenously. We then demonstrated that the exogenous supplementation of BH 4 markedly increased the eNOS dimerization and the NO generation, as well as improved in vivo endothelial repair capacity of early EPCs from PHAs, indicating that BH 4 treatment has beneficial effect on modifying hyperaldosteronemia-caused functional impairment of early EPCs. The MR that mediated the response to aldosterone expressing in early EPCs has been proved previously 15, 16 and was identified in the present study again ( Figure S10 ). Spironolactone, a MR antagonist, has been generally applied in clinic for treatment with PHAs or the condition of secondary activation of renin-angiotensin-aldosterone system such as heart failure and myocardial infarction. The present study showed that oral spironolactone was able to improve in vivo endothelial repair capacity of early EPCs and endothelial function in PHAs. Oral spironolactone also decreased oxidative stress level, reduced BH 4 oxidation, attenuated eNOS uncoupling, and increased NO generation in early EPCs of PHAs. These results demonstrated that hyperaldosteronemia-induced functional impairment of early EPCs was MR dependent and put forward a novel Hyperaldosteronemia whether occurred in PHAs or secondary cases such as patients with acute myocardial infarction or chronic heart failure has been proved to be adverse to cardiovascular outcome. 12, 29, 30 The present study demonstrated the negative effect of hyperaldosteronemia on early EPCmediated endogenous endothelial repair process via the wellestablished simple PHAs avoiding underlying heterogeneous interference of other cardiovascular risk, providing novel evidence to support the hyperaldosteronemia as an independent risk factor for the pathogenesis of atherosclerotic vascular disease. The present study also demonstrated that suppressing oxidative stress or exogenous supplement with BH 4 was beneficial for early EPC function, suggesting that antioxidant therapy and BH 4 supplementation may be novel supplementary treatment means for hyperaldosteronemia particularly in the situation where the high dose of MR antagonist should be avoided because of its side effect in long-term treatment.
Perspectives
The present study demonstrated that the hyperaldosteronemia leads to diminished early EPC-mediated endothelial repair capacity, and the effect is MR dependent. NADPH oxidasederived oxidative stress activation and subsequently oxidative BH 4 degradation, as well as eNOS uncoupling, were responsible for hyperaldosteronemia-caused early EPC dysfunction. MR antagonist, suppressing oxidative stress or exogenous BH 4 supplementation, has a beneficial effect to improve early EPC-mediated endothelial repair capacity, which was impaired by hyperaldosteronemia. Discrimination and intervention of hyperaldosteronemia should draw more attention in clinic practice to prevent and retard the pathogenesis of atherosclerotic vascular disease.
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What Is New?
• Endothelial repair capacity of early endothelial progenitor cells and endothelial function are substantially impaired in hypertensive patients with primary hyperaldosteronemia, and the impairment is more severe than essential hypertension patients with similar blood pressure level.
• Nicotinamide adenine dinucleotide phosphate oxidase-derived oxidative stress activation and subsequently oxidative 5,6,7,8-tetrahydrobiopterin degradation, as well as endothelial nitric oxide synthase uncoupling, are mechanistically related to declined early endothelial progenitor cell endothelial repair capacity of primary hyperaldosteronemias.
• Mineralocorticoid receptor antagonist, suppressing oxidative stress or exogenous 5,6,7,8-tetrahydrobiopterin supplementation, has beneficial effect to improve early endothelial progenitor cell-mediated endothelial repair of PHAs.
What Is Relevant?
• The findings in this study demonstrate a novel mechanism for hyperaldosteronemia contributing to the development of endothelial injury and provide a new evidence to support the hyperaldosteronemia as an independent risk factor for the pathogenesis of atherosclerotic vascular disease.
Summary
The present study demonstrates for the first time that hyperaldosteronemia impairs early endothelial progenitor cell-mediated endothelial repair capacity in addition to elevating blood pressure and provides a novel therapeutic means for increased endothelial repair capacity in hypertensive patients with primary hyperaldosteronemia. 
Novelty and Significance
Supplemental Materials and Methods
Early Endothelial Progenitor Cells (EPCs) Cultivation and Identify
Early EPCs were cultured and identified as described previously. [1] [2] [3] [4] In brief, peripheral blood mononuclear cells (PBMNCs) from subjects were isolated by Ficoll density gradient centrifugation and cultured on fibronectin-coated 6-well plates in endothelial cell basal medium-2 (EBM-2) supplemented with endothelial growth medium-SingleQuots exactly as indicated by the manufacturer (Clonetics, San Diego, CA, USA). After 4 days culture, nonadherent cells were removed by washing plates with phosphate buffered solution (PBS), and new medium was applied. Adherent cells were maintained for 7 days and then used for early EPC experiments. Early EPCs were defined as cells dually positive for DiI-acLDL (0.02 mg/mL; Invitrogen, Carlsbad, CA, USA) uptake and FITC-labelled BS-1 lectin (0.01 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) binding as described previously. 
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In Vitro Migration Assay Migration assays were performed as described previously. [1] [2] [3] [4] In brief, a total of 2 x 10 4 early
EPCs were isolated, resuspended in 250 μL EBM-2 and pipetted at the 7th day in the upper chamber of a modified Boyden chamber (Costar Transwell ® assay, 8 μm pore size, Corning, NY, USA). The chamber was placed in a 24-well culture dish containing 500 μL EBM-2 supplemented with 50ng ng/mL vascular endothelial growth factor (VEGF) and 100 ng/mL stromal cell-derived factor-1 (SDF-1). After 24 hours incubation at 37°C, transmigrated cells were counted by at least 3 independent investigators blinded to treatment randomly.
In Vitro Assay of Adhesion on fibronection in flow
Laminar flow assays were performed as described previously. 1, 3 In brief, dishes were coated with fibronectin (10 mg/mL), and early EPCs (5×10 5 /mL) were resuspended in assay buffer (HEPES-buffered Hank's balanced salt solution, 1 mmol/L Mg 2+ /Ca 2+ , and 0.5% BSA) and perfused into the flow chamber (proprietary item; commercially obtained from RWTH Aachen University) at a shear rate of 1.5 dyn/cm 2 for 4 minutes at 37°C. The number of adherent cells after 4 minutes was quantified in multiple fields by at least 3 independent investigators blinded to treatment randomly.
Circulating EPCs Sorted by FACS Analysis
Circulating EPCs were evaluated as the number of CD34 + ⁄KDR + or CD133 + ⁄KDR + cells per 10 5 PBMNCs of subjects by FACS (Beckman-Coulter) analysis as previously described.
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Animal Model and in Vivo Endothelial Repair Assay
Male NRMInu/nu athymic nude mice (SLAC laboratory animal center, Shanghai, China), aged 8 to 10 weeks, were used to allow injection of human early EPCs. Animals were anesthetized with ketamine (100 mg/kg IP) and xylazine (5 mg/kg IP). Carotid artery denudated injury was performed as described previously. [1] [2] [3] [4] Surgery was carried out using a dissecting microscope. The left carotid artery was exposed via a midline incision on the ventral side of the neck. The bifurcation of the carotid artery was located, and two ligatures were placed around the external carotid artery, which was then tied off with the distal ligature. An incision hole was made between the two ligatures to introduce the denudation device. The curved flexible wire (0.35-mm diameter) was introduced into the common carotid artery, and passed three times in order to denude endothelium. The wire was then removed, and the external carotid artery was tied off proximal to the incision hole with the proximal ligature. The endothelial denudation of carotid artery was identified by Evans Blue staining (Online Figure S1A ) and electron microscope scanning (Online Figure S1B) and FITC-labelled BS-1 lectin staining (Online Figure S1C) . Early EPCs (5×10 5 cells) were resuspended in 100 μL of prewarmed PBS (37°C) and transplanted 3 hours after carotid artery injury via tail vein injection with a 27-gauge needle and the same volume of PBS was injected into placebo mice. 3 days after carotid injury, endothelial repair was evaluated as reendothelialization area of the denudated endothelial zone by staining with 100 μL of solution containing 3% Evans Blue dye via tail vein injection as described in detail previously. [1] [2] [3] [4] Early EPCs from each subject were transfused into 2 nude mice with carotid endothelial injury, the mean values of the reendothelialization area were used for analysis. All experimental protocols complied with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the Animal Care and Use Committees of Sun Yat-sen University (Guangzhou, China).
Detection of Homing of Early EPCs to Carotid Artery by Confocal Laser Scanning Microscopy Analysis
Early EPCs (5×10 5 cells) cultured from health subjects (HSs; n=5) were were injected into the tail vein of nude mice with carotid injury. After 24 hours the animals were sacrificed, the injured section of the carotid arteries and the corresponding uninjured section of the contralateral carotid arteries were collected and dissected. After fixed with 4% (v/v) paraformaldehyde, the dissected carotid arteries were respectively incubated with phycoerythrin (PE)-conjugated monoclonal mouse anti-human CD14 antibody (1:100; abCAM, Cambridge, MA, USA) overnight at 4℃ to label the injected human early EPCs (red signal) and FITC-labelled BS-1 lectin (0.01 mg/mL) for 1 hour at room temperature to stain the endothelium layer (green signal), finally the DAPI staining was used for nuclei staining (blue signal). Then the confocal laser scanning microscopy (Carl Zeiss LSM 710, German) analysis was used to observe the homing early EPCs.
Detection of Homing of Early EPCs to Carotid Artery by FACS Analysis
Early EPCs (5×10 5 cells) cultured from HSs (n=5) were transduced and injected into the tail vein of nude mice with carotid injury. After 24 hours, the animals were sacrificed, blood was immediately removed, injured section of carotid arteries and the corresponding uninjured section of contralateral carotid arteries were dissected. These carotid arteries were then opened and incubated with 0.2% collagenase for 30 minutes at 37 °C, and then flushed with pre-cooled washing buffer (10 mM HEPES, 0.1% BSA in HBSS). Then the cell suspension was filtered through a 100 μm mesh and centrifuged at 1200 rpm for 5 minutes. The cells were resuspended and fixed with 4% (v/v) paraformaldehyde, the cells then incubated with PE-conjugated monoclonal mouse anti-human CD14 antibody (abCAM) for 1 hour at room temperature and analyzed by the BD FACSCanto II system (BD Biosciences, San Jose, California, USA).
Endothelial Function Evaluation
Flow-mediated dilation (FMD) of the brachial artery was performed in subjects by high-resolution ultrasound (Acuson 128XP⁄10, Mountain View, CA, USA, with a 7.0 MHz linear-array transducer) to evaluate the endothelial function as previously described.
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Measurement of Reactive Oxygen Species (ROS) via Fluorescence Microscope
Intracellular production of ROS in early EPCs was measured semi-quantitatively by 2',7'-dichlorodihydrofluorescein diacetate (DCF; Alexis, Plymouth Meeting, PA, USA) according to the manufacturer's instructions. Early EPCs were loaded with DCF (10 μmol/L) for 20 minutes at 37°C, washed 3 times in PBS, and then observed with a fluorescence microscope equipped with a high-resolution digital CCD camera (Olympus, Tokyo, Japan). Images were collected by single rapid scans with identical parameters being used for all of the samples. Fluorescence intensity data were quantified in 4 independent experiments.
Electron Paramagnetic Resonance (EPR) Spectroscopy Analysis of Early EPC Superoxide Production
Early EPC superoxide (O 2 -. ) production was measured by EPR spectroscopy analysis using the paramagnetic trap 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CM-H; Noxygen, Denzlingen, Germany) as following the protocol described by other research lab. 5, 6 In brief, 2.5x10 5 early EPCs were resuspended in 46 μL Krebs-Hepes-buffer containing diethyldithiocarbamic acid sodium salt (DETC) and deferoxamine. EPR measurements were performed after CM-H addition in 50 μL glass capillaries. EPR spectra were recorded using an EPR spectrometer (Brueckner; Leonberg, Germany). Early EPC O 2 -. production was determined by following the oxidation of CM-H to paramagnetic CM*. EPR instrumental settings were as follows: field sweep 100G, sweep time 60 seconds, microwave frequency 9.86GHz, microwave power 20mW, modulation amplitude 1G.
cGMP Assay
To evaluate NO output in early EPCs, intracellular cGMP concentration was measured using a enzyme immunoassay system (R&D Systems, Minneapolis, MN, USA). The cells were washed with serum-free medium followed by stimulated with 50 ng/mL VEGF, and then detected with the enzyme immunoassay kit as indicated by the manufacturer instruction.
L-arginine/L-citrulline Conversion Assay
The enzymatic reaction catalyzed by eNOS converts the L-arginine into L-citrulline while the equimolar amounts of NO generates. Therefore, L-citrulline production serves as a marker of NO generation in this enzymatic reaction. Early EPCs were washed with PBS and equilibrated in HEPES buffer (pH 7.4) for 1 hour at 37℃. Then 0.5 μmol/L L-arginine (Sigma-Aldrich) and 10 minutes later 1 μmol/L of the calcium ionophor A23187 (Sigma-Aldrich) were added. After incubation with another 15 minutes at 37℃ the reaction was stopped by lysing cells with 96% ethanol on ice. Cell extract was pooled and dried under vacuum. The derivatization was performed by the reagent solution consisted of methanol/ethanol/triethylamine/ultra-pure water/phenylisothiocyanate (PITC) = (6/1/1/1/1, v/v/v/v/v), which was made freshly. The mobile phase A consisted of 0.12 mmol/L sodium acetate and 2.5 μmol/L EDTA buffer with 2.5% (v/v) acetonitrile (pH 6.5). The mobile phase B consisted of 15% methanol, 45% acetonitrile, and 40% ultra-pure water. Chromatography separation was performed on a high performance liquid chromatography (HPLC) system (Shimadzu LC-20AD, Kyoto, Japan).
Measurements of Intracellular Biopterin Content in Early EPCs
The intracellular biopterin content was detected by HPLC system following the protocol described by other research lab. 7 Biopterin content was determined in early EPCs lysate after iodine oxidation with KI/I 2 under acidic and basic conditions using HPLC system (Shimadzu) with a fluorescence detector. The amount of BH 4 was determined from the difference between total (BH 4 plus BH 2 plus biopterin) and alkaline-stable oxidized (BH 2 plus biopterin) biopterin.
Real Time-PCR Analysis
The primers of p47 phox used for quantitative real-time RT-PCR were purchased from Invitrogen (Carlsbad, Calif, USA). Total RNA was isolated with the mRNA abstraction kit (Tiangen Biotech, Beijing, China). The experiments were performed using SYBR One-Step quantitative RT-PCR kits (Invitrogen) according to the manufacturer's instructions. GAPDH was used as the internal control.
Western Blot Analysis
Early EPC protein was harvested by cell lysis buffer (Cell Signaling Technology, Boston, MA, USA). For immune-blotting analysis of the dimeric form of eNOS, samples were subjected to 6% to 9% gradient polyacrylamide gels without preheating, and the temperature of the gels was maintained at 4°C during electrophoresis (low-temperature SDS-PAGE). To separate membrane and cytosolic protein fraction for evaluating p47 phox translocation, we used the ProteoExtract Subcellular Proteome Extraction kit (Calbiochem, Darmstadt, Germany) according to the manufacturer's instructions. The following primary antibodies were used: rabbit anti-human antibodies for eNOS (1:1000; Cell Signaling Technology), NADPH oxidase subunits p47 phox (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), NOX1
(1:1000; Santa Cruz Biotechnology), NOX2 (1:1000; Santa Cruz Biotechnology), NOX4 (1:1000; Santa Cruz Biotechnology), actin (1:2000; Cell Signaling Technology). Proteins were visualized with HRP-conjugated anti-rabbit IgG (1:2000; Cell Signaling Technology) then followed by use of the ECL chemiluminescence system (Cell Signaling Technology). The density of the bands was quantified using the NIH Image program. Each experiment was repeated at least 3 times.
Small-interfering RNA Transfection
To knock down the expression of NADPH oxidase subunit p47 phox of early EPCs, the p47 phox -siRNA duplex (sc-29422) was purchased from Santa Cruz Biotechnology. After determining optimal transfection conditions, cultured human early EPCs were transfected with siRNA according to the manufacturer's protocol (data not shown). A scrambled-siRNA (sc-36869, Santa Cruz Biotechnology) was used as a negative control. After 24 hours of transfection, the early EPCs were used for subsequent measurement. Table   Supplemental Table S1 as mean ± SEM. PHAs = primary hyperaldosteronemia patients; EHs = essential hypertension patients; HSs = healthy subjects; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL-c = low-density lipoprotein cholesterol; FBG = fast blood glucose. Medication: In the present study, there was not any included subject who was being treated with the medication (such as statins, insulin-sensitizing agents, ACEIs or ARBs) which has possible effect on early endothelial progenitor cell bioactivity according to the excluded criterion and drug withdrawal protocol.
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Supplemental Figures and Figure Legends
Supplemental Figure S1 Figure S1. Identification of endothelial denudated injury in carotid artery of nude mice. A, Endothelium injury was confirmed by Evans Blue dye staining immediately after wire-mediated carotid artery injury in nude mice. Representative photographs: injured artery and contralateral uninjured artery (arteries without discission). B, Electron microscope pictures (×1000 magnification) showed that endothelial layer was intact on contralateral uninjured carotid artery (upper panel) and endothelial layer was denudated on the injured carotid artery (low panel). C, Confocal laser scanning microscopy analysis (×400 magnification): the endothelial layer was visualized by FITC-lectin-stained (green signal), and DAPI staining was used for nuclei staining (blue signal). The uninjured zone of the artery covered by intact endothelial layer (upper panel), the endothelial layer was denudated and the sub-endothelial layer was exposed on the injured zone of the artery (low panel). Figure S2 . Detection of homing of early endothelial progenitor cells (EPCs) to the injured carotid arteries. A, Confocal laser scanning microscopy analysis (×400 magnification): the endothelial layer was visualized by FITC-lectin-stained (green signal), DAPI staining was used for nuclei staining (blue signal). Phycoerythrin (PE)-conjugated monoclonal mouse anti-human CD14 antibody-labeled early EPCs (red signal) were detected beneath the endothelial layer by repeated serial imaging with increasing depth of the endothelial repair zone of the injured carotid artery (A a-c) and the sub-endothelial layer where the denudated endothelium was not repaired yet (A d-f) . B, Early EPCs from healthy subject (HSs; n=5) were injected into the tail vein of nude mice with carotid injury. After 24 hours, the injured and the corresponding section of the contralateral uninjured carotid artery were homogenized respectively, the number of PE-conjugated monoclonal mouse anti-human CD14 antibody-labeled early EPCs was quantified by using fluorescence-activated cell sorter analysis. C, HUVECs were injected into the tail vein of nude mice with carotid injury as the negative control. After 3 days, the effect of HUVECs injection for endothelial repair was not different compared with PBS injection; Early EPCs injection showed a distinct effect to improve endothelial repair compared with PBS injection or HUVECs injection (n=5 per group). * P<0.01 versus reendothelialization area of PBS injection group or HUVECs injection group. Figure S3 . The early EPCs-mediated endothelial repair after carotid injury at different time points: 3, 7, 14 days. A, Reendothelialization area at 3 days, 7 days, and 14 days after carotid injury in nude mice with transplantation of early EPCs from healthy subjects (HSs; n=5), essential hypertension patients (EHs; n=5), and primary hyperaldosteronemia patients (PHAs; n=5). Representative photographs showed in B. * P<0.05 versus early EPC in vivo endothelial repair capacity of HSs, # P<0.05 versus versus early EPC in vivo endothelial repair capacity of EHs. Figure S4 . In vitro early endothelial progenitor cells (EPCs) function assays. A, Quantification analysis of migration to vascular endothelial growth factor/stromal cell-derived factor-1 of early EPCs from healthy subjects (HSs; n=12), essential hypertension patients (EHs; n=10) or primary hyperaldosteronemia patients (PHAs; n=10) before and after treatment with spironolactone (Spi). The representative photographs showed in (B; ×200 magnification, scale bar = 100μm). C, Quantification analysis of early EPC adhesion on fibronectin in flow of early EPCs from HSs (n=12), EHs (n=10) or PHAs (n=10) before and after treatment of Spi. The representative photographs showed in (D; ×200 magnification, scale bar = 100 μm). 
Supplemental Figure S9
Figure S9. The effect of L-NAME or apocynin on oxidative stress of early endothelial progenitor cells (EPCs) from primary hyperaldosteronemia patients (PHAs). A and B, Electron paramagnetic resonance spectroscopy analysis showed that the apocynin rather than L-NAME inhibited superoxide production of early EPCs from PHAs; n=5 per group. C, Intracellular reactive oxygen species (ROS) production of early EPCs from PHAs evaluated via 2',7'-dichlorodihydrofluorescein diacetate (DCF)-fluorescence analysis was suppressed obviously by apocynin rather than L-NAME; n=5 per group. 
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